Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage

被引：3
|
作者：
Takasaki, Kaoru [1 ]
Hehir, David [2 ,3 ,4 ,5 ]
Raffini, Leslie [6 ,7 ]
Samelson-Jones, Benjamin J. [6 ,7 ,8 ]
Shih, Evelyn [1 ,9 ,10 ,11 ]
Dain, Aleksandra Sarah [1 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol & Oncol, 3615 Civic Ctr Blvd,Room 314E, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA USA
[3] Childrens Hosp Philadelphia, Div Cardiac Crit Care, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Anesthesia, Philadelphia, PA USA
[5] Univ Penn, Perelman Sch Med, Dept Crit Care, Philadelphia, PA USA
[6] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA USA
[7] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[8] Raymond G Perelman Ctr Cellular & Mol Therapeut, Philadelphia, PA USA
[9] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA USA
[10] Univ Penn, Dept Neurol, Philadelphia, PA USA
[11] Univ Penn, Dept Pediat, Philadelphia, PA USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 06期
基金：
美国国家卫生研究院;
关键词：
VENOUS THROMBOSIS;
D O I：
10.1002/pbc.29484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] FEIBA AND ANDEXANET ALFA FOR THE REVERSAL OF APIXABAN AND RIVAROXABAN IN UNCONTROLLED HEMORRHAGE
    Ice, Calvin
    Gurka, Matthew
    Parker, Jessica
    Hunt, Aleah
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 449 - 449
  • [2] Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage
    Michelle Lipski
    Stacy Pasciolla
    Kevin Wojcik
    Brian Jankowitz
    Lauren A. Igneri
    Journal of Thrombosis and Thrombolysis, 2023, 55 : 519 - 526
  • [3] Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage
    Lipski, Michelle
    Pasciolla, Stacy
    Wojcik, Kevin
    Jankowitz, Brian
    Igneri, Lauren A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2023, 55 (03) : 519 - 526
  • [4] Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage
    Mark L. Vestal
    Kimberly Hodulik
    Jennifer Mando-Vandrick
    Michael L. James
    Thomas L. Ortel
    Matthew Fuller
    Maria Notini
    Mark Friedland
    Ian J. Welsby
    Journal of Thrombosis and Thrombolysis, 2022, 53 : 167 - 175
  • [5] Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage
    Vestal, Mark L.
    Hodulik, Kimberly
    Mando-Vandrick, Jennifer
    James, Michael L.
    Ortel, Thomas L.
    Fuller, Matthew
    Notini, Maria
    Friedland, Mark
    Welsby, Ian J.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 53 (01) : 167 - 175
  • [6] Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
    Rauch, Sebastian
    Mueller, Hans-Peter
    Dreyhaupt, Jens
    Ludolph, Albert C.
    Kassubek, Jan
    Althaus, Katharina
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (12)
  • [7] Expanding intracranial hemorrhage after administration of andexanet alfa
    Riley, Matthew
    Keen, Mary
    Baum, Regan
    Akpunonu, Peter
    CLINICAL TOXICOLOGY, 2021, 59 (11) : 1143 - 1143
  • [8] Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
    Bradshaw, Paige Garber
    Keegan, Shaun Patrick
    Droege, Molly Elizabeth
    Dykes, Nicole Jade Harger
    Ernst, Neil Edward
    Foertsch, Madeline Jane
    Makley, Amy Teres
    Mueller, Eric William
    Philpott, Carolyn Dosen
    Srinivasan, Vasisht
    Winter, Jessica Brooke
    Goodman, Michael D.
    Droege, Christopher Allen
    PHARMACOTHERAPY, 2022, 42 (10): : 780 - 791
  • [9] ANDEXANET ALFA VERSUS 4-FACTOR PCC FOR REVERSAL OF INTRACRANIAL HEMORRHAGE ASSOCIATED WITH FACTOR XA
    Semon, Gregory
    Straughn, Angela
    Hardman, Claire
    Steel, Barbara
    Ekeh, Akpofure
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 301 - 301
  • [10] PHASE 3 OF ANDEXANET ALFA FOR REVERSAL OF APIXABAN AND RIVAROXABAN ANTICOAGULATION IN OLDER SUBJECTS
    Crowther, Mark
    Gold, Alex
    Lu, Genmin
    Leeds, Janet
    Wiens, Brian
    Conley, Pamela
    Connolly, Stuart
    Curnutte, John
    CRITICAL CARE MEDICINE, 2015, 43 (12)
12345